Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

PLSE 12.19.2024

Full Press ReleaseSEC FilingsOur PLSE Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities

HAYWARD, Calif.--(BUSINESS WIRE)--Dec. 19, 2024--Pulse Biosciences, Inc.(Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse StimulationTM (NPSTM) technology, today announced that, onDecember 18, 2024, the Company’s Co-Chairman and majority shareholder,Robert W. Duggan, exercised all of the warrants he acquired in the Company’s 2024 rights offering, corresponding to$58.4 milliontotaling to 5,306,156 shares of Company common stock.Mr. Dugganalso confirmed that, fromDecember 11, 2024through this pastFriday, December 13, 2024, he has purchased an additional 156,714 shares ofPulse Biosciences. These transactions bring Mr. Duggan’s current ownership in the Company to approximately 70%.

About Pulse Biosciences®

Pulse Biosciencesis a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFATM technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.Pulse Biosciencesis now headquartered inMiami, Floridaand maintains its office inHayward, California.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks ofPulse Biosciences, Inc.inthe United Statesand other countries.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241219059064/en/

Investors:Pulse Biosciences, Inc.Darrin Uecker, CTO orKevin Danahy, CCOIR@pulsebiosciences.comorGilmartin GroupPhilip Trip Taylor415.937.5406philip@gilmartinir.com

Rights Offering Information, Subscription and Warrant Agent:Broadridge Corporate Issuer Solutions, LLCAttn:BCIS Re-Organization Dept.P.O. Box 1317Brentwood, NY11717-0718888.789.8409shareholder@broadridge.com

Source:Pulse Biosciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com